VELPATASVIR AND SOFOSBUVIR

12830 reported adverse events

Drug classes: Hepatitis C Virus NS5A Inhibitor [EPC] Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC]

These side effects are most commonly reported by patients taking VELPATASVIR AND SOFOSBUVIR:

# Side effect Count
0 FATIGUE 2628
1 HEADACHE 2218
2 NAUSEA 1178
3 DIARRHOEA 664
4 DRUG INEFFECTIVE 558
5 INSOMNIA 514
6 HEPATITIS C 413
7 TREATMENT FAILURE 337
8 VOMITING 330
9 DEATH 312
See all common reactions for VELPATASVIR AND SOFOSBUVIR

VELPATASVIR AND SOFOSBUVIR is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 HEPATITIS C CORE ANTIBODY POSITIVE 2 0.3333
1 PORTAL VEIN FLOW DECREASED 4 0.0976
2 HEPATITIS C RNA 4 0.0870
3 HEPATITIS C VIRUS TEST POSITIVE 45 0.0765
4 HEPATITIS C RNA POSITIVE 12 0.0702
5 GENOTYPE DRUG RESISTANCE TEST POSITIVE 72 0.0700
6 GASTRIC NEUROENDOCRINE CARCINOMA 2 0.0588
7 CHILD-PUGH-TURCOTTE SCORE INCREASED 5 0.0588
8 ALPHA 1 FOETOPROTEIN ABNORMAL 4 0.0400
9 HEPATITIS C RNA INCREASED 13 0.0380
See all enriched reactions for VELPATASVIR AND SOFOSBUVIR